Drugs / DOTAP:Chol-fus1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00059605 | Mar 2003 → Apr 2011 | lung cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DOTAP:Chol-fus1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00059605 ↗ |
| Known as | DOTAP:chol-TUSC2 | “Patients with recurrent and/or metastatic lung cancer previously treated with platinum-based chemotherapy were treated with escalating doses of intravenous...” PMID 22558101 ↗ Apr 2012 |
| Action | Restore | “The idea is to try to replace this gene in lung cancer cells.” NCT00059605 ↗ |
| Route | Intravenous | “administered intravenously” NCT00059605 ↗ |
| Target | TUSC2 | “encapsulating a TUSC2 expression plasmid” PMID 22558101 ↗ Apr 2012 |